Holen Sie sich die Stockscreener-App
4.5106
0.67%
0.0306
Schlusskurs vom Vortag:
$4.48
Offen:
$4.46
24-Stunden-Volumen:
18,449
Relative Volume:
0.03
Marktkapitalisierung:
$260.05M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
86.08
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
-0.44%
1M Leistung:
-7.01%
6M Leistung:
-15.07%
1J Leistung:
+29.97%
1-Tages-Spanne:
$4.46
$4.5106
1-Wochen-Bereich:
$4.215
$4.61
52-Wochen-Spanne:
$3.46
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vergleichen Sie VNDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.5106 | 260.05M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.58 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.74 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
667.61 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.47 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
HC Wainwright Reaffirms Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Vanda, Anaptys Join on Development Pact - Baystreet.ca
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug - MSN
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Washington D.C. Pharma Co. Receives FDA Acceptance - Streetwise Reports
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts - Benzinga
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts - The Business Journals
Vanda granted hearing to discuss FDA rejection of application for tradipitant - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug By Investing.com - Investing.com South Africa
Vanda granted hearing to discuss FDA rejection of application for tradipitant ( - Seeking Alpha
Vanda Pharmaceuticals Files New Drug Application - TipRanks
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA - TipRanks
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PR Newswire
Vanda Loses US Trade Secrets Battle Over Fanapt And Hetlioz Generics - News & Insights
US Claims Court rules Vanda’s trade secrets not so secret - BioWorld Online
Vanda Loses US Trade Secrets Battle On Fanapt And Hetlioz ANDA Products - News & Insights
Equities Analysts Issue Forecasts for VNDA FY2025 Earnings - MarketBeat
Vanda Loses Takings Clause Arguments In Trade Secret Fight - Law360
Vanda Pharmaceuticals (NASDAQ:VNDA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
Vanda asserts FDA review of tradipitant was flawed - MSN
Insomnia Market Overall Study Report 2025-2032 | Vanda - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Yahoo Finance
Pugilistic Vanda Collects Another NOOH As US FDA Defends Tradipitant Turndown - News & Insights
DC Circuit Skeptical of FDA Rejection of Vanda’s Jet Lag Drug - Bloomberg Law
High Court Rejects Vanda Suit Over Medicaid Drug Definition - Bloomberg Law
Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - BioSpace
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner - Marketscreener.com
Vanda Pharmaceuticals Challenges FDA Over Gastroparesis Drug Rejection in Open Letter - StockTitan
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now? - Yahoo Finance
StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.75%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):